DUBLIN: The "Pharmaceutical Safety Assessment Global Market Report 2025" has been added to ResearchAndMarkets.com's offering.

The pharmaceutical safety assessment market has demonstrated significant growth, expanding from $10.47 billion in 2024 to an anticipated $11.32 billion in 2025, reflecting a CAGR of 8.1%. This growth stems from heightened demand for preclinical research, stricter drug safety regulations, increased outsourcing to contract research organizations, advances in animal model studies, and early adoption of cell-based assays.

Projections indicate that the market will continue on this upward trajectory, reaching $15.64 billion by 2029 at a CAGR of 8.4%. This anticipated expansion correlates with biological and biosimilars development, increased use of in silico toxicology platforms, investment in personalized medicine, regulatory emphasis on alternative testing methods, and burgeoning demand for high throughput screening technologies. The forecast period highlights major trends, including artificial intelligence integration in toxicity prediction, a shift from animal testing to organ-on-chip systems, computational modeling expansion, pharma-tech collaborations, and a focus on predictive biomarkers for safety assessment.

Clinical trials bolster the growth of the pharmaceutical safety assessment market by providing crucial data on drug efficacy and safety. The surge in the number of trials, driven by the demand for new treatment options, reflects the global commitment to advancing healthcare solutions. As of September 2025, 554,798 studies were registered on ClinicalTrials.gov, underscoring their role in enhancing pharmaceutical safety assessment through rigorous human studies, adverse reaction monitoring, and safe dosage determination.

Leading market players are focusing on advanced strategies like the lifecycle-wide risk management approach, safeguarding patient protection through all drug development phases. Notable initiatives include the International Society for Pharmaceutical Engineering (ISPE) launching *Enabling Global Pharma Innovation Delivering for Patients* in October 2024, targeting industry-wide innovation and overcoming regulatory barriers.

Significant market movements include Groupe ProductLife S.A.S.'s acquisition of Stragen Services SAS in January 2025, aimed at enhancing its European presence and offering integrated regulatory and safety solutions in pharmaceutical safety assessment.

Prominent players in this market include IQVIA Holding Inc., LabCorp, Thermo Fisher Scientific, Charles River Laboratories, ICON plc, among others. North America led the market in 2024, with Asia-Pacific poised for the fastest growth in the future.

Report Scope

The report investigates the most substantial and rapidly expanding markets within the pharmaceutical safety assessment sector. It explores the interplay between this market and broader economic, demographic, and related market forces, unveiling potential influences from technological disruptions to consumer behavior shifts.

Inclusive of market size evaluations, growth forecasts, segmentations, and in-depth regional breakdowns, the report details historical and future market progression by area. The competitive landscape is thoroughly mapped, offering insights into market dynamics, key competitor strategies, and significant financial transactions that have steered market evolution.

The report categorizes the market by type, drug type, phase, and end-user, allowing for precise market segmentation analysis:

• Types: In-Vitro Safety Assessment, In-Vivo Safety Assessment, Computational Safety Assessment.
• Drug Types: Biological Drugs, Chemical Drugs.
• Phases: Preclinical, Clinical (Phase I-III), Post-Market Surveillance (Phase IV).
• End Users: Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies, Academic and Research Institutions, Contract Research Organizations (CROs).
• Subsegments: Diverse methodologies in each assessment type, such as QSAR Modeling and PBPK Modeling.

Featured Companies: Prominent industry players include IQVIA Holding Inc., LabCorp, Thermo Fisher Scientific, and Charles River Laboratories, among others.

Geographical Insights: The report traverses major markets in Australia, Brazil, China, France, Germany, and several other significant nations, distributed over regions such as Asia-Pacific, Western Europe, and North America.

With five years of historical data and ten years of forecast, the report delineates market dynamics, allowing businesses to align strategies with market evolutions effectively. Data segmentation includes historical and forecast figures for countries and regions, competitor market shares, and segmented markets.

Report Format: Delivered as PDF, Word, and Excel Data Dashboard formats for ease of use.

Key Attributes

The companies featured in this Pharmaceutical Safety Assessment market report include:

• IQVIA Holding Inc.
• LabCorp (formerly Covance)
• Thermo Fisher Scientific (PPD)
• Charles River Laboratories
• ICON plc
• Parexel International Corp.
• Syneos Health
• Eurofins Scientific SE
• Wuxi Biologics Inc.
• SGS SA
• Medpace Holdings Inc.
• Fujifilm Wako (Fujifilm Corp.)
• Pharmaron Beijing Co. Ltd.
• Inotiv (incl. Envigo)
• Evotec (Cyprotex)
• Intertek Group
• Altasciences Inc.
• Aragen Life Sciences Ltd.
• CTI Clinical Trial and Consulting Inc.
• ChemDiv Inc.
• Frontage Laboratories
• Medicilon Inc.
• Biotoxtech Co. Ltd.
• BioIVT
• Accelera Srl

For more information about this report visit https://www.researchandmarkets.com/r/1nhkl9

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Fonte: Business Wire